Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Urologic Neoplasms × Administration, Intravesical × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

tislelizumab 1 pembrolizumab 1 enfortumab vedotin 1 cabozantinib 1 VMBP protocol 1 Nivolumab 1 Neoadjuvant Therapy 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Administration, Intravesical 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03636256 2023-08-14

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed

36 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡